Roschewski M, Phelan JD, Wilson WH (2020) Molecular classification and treatment of diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Cancer J 26(3):195–205

Article  PubMed  PubMed Central  CAS  Google Scholar 

Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A, Julamanee J, Chansung K et al (2017) Non-Hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features, and survival from Thailand. Hematol Oncol 23:28–36

Google Scholar 

Jelicic J, Juul-Jensen K, Bukumiric Z, Clausen MR, Al-Mashhadi AL, Pedersen RS et al (2023) Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J 13(1):157. https://doi.org/10.1038/s41408-023-00930-7

Shi X, Liu X, Li X, Li Y, Lu D, Sun X et al (2021) Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and international prognostic index: a multicenter retrospective study. Front Oncol 16:11

Google Scholar 

International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994

Article  Google Scholar 

Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861

Article  PubMed  CAS  Google Scholar 

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Ri Fisher et al (2022) The use of molecular profiling to predict survival after chemotherapy for diffuse large B cell lymphoma. N Engl J Med 346:1937–47

Article  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282

Article  PubMed  CAS  Google Scholar 

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S et al (2015) Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embeded tissue biopsies. J Clin Oncol 33:2248–2256

Article  Google Scholar 

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC et al (2022) The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140(11):1229–1253. Available from: https://ashpublications.org/blood/article/140/11/1229/485458/The-International-Consensus-Classification-of. Accessed 1 Nov 2024

Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720–48. https://doi.org/10.1038/s41375-022-01620-2

Article  PubMed  PubMed Central  Google Scholar 

Green TM, Young KH, Visco C et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460–3467

Article  PubMed  CAS  Google Scholar 

Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P et al (2019) MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy, Blood 114:3533–3537

Google Scholar 

Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R et al (2010) Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 28:3360–3365

Article  PubMed  CAS  Google Scholar 

Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC et al (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP regimen consortium program study. Haematologica 98:255–63. https://doi.org/10.3324/haematol.2012.066209

Article  PubMed  PubMed Central  CAS  Google Scholar 

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459

Article  PubMed  PubMed Central  CAS  Google Scholar 

Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253–2263

Article  PubMed  CAS  Google Scholar 

Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A et al (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20):4021–4031

Article  PubMed  PubMed Central  CAS  Google Scholar 

Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D et al (2015) MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemtherapy: a GELA/LYSA study. Blood 126:2466–2474

Article  PubMed  CAS  Google Scholar 

Kojima M, Nishikii H, Takizawa J, Aoki S, Noguchi M, Chiba S et al (2013) MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy:multicenter analysis of Japanese patients with diffuse large B-cell lymphoma. Leuk Lymphoma 54:2149–2154

Article  PubMed  CAS  Google Scholar 

Younes A, Rosenthal A (2017) High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: double hit and triple hit lymphoma ad double expressing lymphoma. Blood Rev 31(2):37–42

Article  PubMed  Google Scholar 

Bellas C, García D, Vicente Y, Kilany L, Abraira V, Navarro B et al (2014) Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma. PLoS ONE 9(6):e98169

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Wang H, Ren C, Yu H, Fang W, Zhang N et al (2018) Correlation between C-MYC, BCL-2, and BCL-6 protein expression and gene translocation as biomarkers in diagnosis and prognosis of diffuse large B-cell lymphoma. Front Pharmacol 9:1497

Article  PubMed  CAS  Google Scholar 

Swerdlow SH (2014) Diagnosis of ’double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program 2014(1):90–99

Article  PubMed  Google Scholar 

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378(15):1396–1407

Article  PubMed  PubMed Central  CAS  Google Scholar 

He X, Chen Z, Fu T, Jin X, Yu T, Liang Y et al (2014) Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer 14:153

Article  PubMed  PubMed Central  Google Scholar 

Huang JJ, Xia Y, Wang Y, Liu PP, Bi XW, Sun P et al (2016) A comparison of R-EPOCH and R-CHOP as a first-line regimen inde novoDLBCL patients with high Ki-67 expression in a single institution. Oncotarget 7(27):41242–41250

Article  PubMed  PubMed Central  Google Scholar 

Yimpak P, Bumroongkit K, Tantiworawit A, Rattanathammethee T, Aungsuchawan S, Daroontum T (2024) Immunohistochemistry-based investigation of MYC, BCL2, and Ki-67 protein expression and their clinical impact in diffuse large B-cell lymphoma in upper Northern Thailand. PLoS ONE 19(7):e0307253-e307263

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhan J, Yang S, Zhang W, Zhou D, Zhang Y, Wang W et al (2022) DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: a single-center retrospective study and meta-analysis. Medicine (Baltimore) 101(38):e30620

Article  PubMed  Google Scholar 

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826–833

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN et al (2019) Treatment of patients with relapsed/refractory non-Hodgkin lymphoma with venetoclax: a single-center evaluation of off-label use. Clin Lymphoma Myeloma Leuk 19(12):791–798